Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CD19/CD20/CD22 targeted CAR-T(Zhengzhou University) in Chronic Lymphocytic Leukemia: NCT06647329 Clinical Landscape Report 2026
15 October 2026
NCT06647329 clinical landscape for Chronic Lymphocytic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zirconium-89 Labelled Vartumab in Recurrent Colon Cancer: NCT06645808 Clinical Landscape Report 2026
15 October 2026
NCT06645808 clinical landscape for Recurrent Colon Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Meldonium hydrate in Metastatic Renal Cell Carcinoma: NCT06648902 Clinical Landscape Report 2026
15 October 2026
NCT06648902 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trastuzumab in Triple Negative Breast Cancer: NCT06649331 Clinical Landscape Report 2026
15 October 2026
NCT06649331 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ruxotemitide in Melanoma: NCT06651151 Clinical Landscape Report 2026
15 October 2026
NCT06651151 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Orelabrutinib in Diffuse Large B-Cell Lymphoma: NCT06647940 Clinical Landscape Report 2026
15 October 2026
NCT06647940 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ATT-001 in Glioblastoma Multiforme: NCT06650605 Clinical Landscape Report 2026
15 October 2026
NCT06650605 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: NCT06649812 Clinical Landscape Report 2026
15 October 2026
NCT06649812 clinical landscape for Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and…
9 min read
Omomyc in Osteosarcoma: NCT06650514 Clinical Landscape Report 2026
15 October 2026
NCT06650514 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
68Ga-NYM096 in Renal Cell Carcinoma: NCT06649682 Clinical Landscape Report 2026
15 October 2026
NCT06649682 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06649851 Clinical Landscape Report 2026
15 October 2026
NCT06649851 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zanubrutinib in Diffuse Large B-Cell Lymphoma: NCT06652165 Clinical Landscape Report 2026
15 October 2026
NCT06652165 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.